On Friday, Vir Biotechnology Inc (NASDAQ: VIR) was 4.73% up from the session before settling in for the closing price of $5.28. A 52-week range for VIR has been $4.95 – $14.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 423.44%. When this article was written, the company’s average yearly earnings per share was at 12.21%. With a float of $87.46 million, this company’s outstanding shares have now reached $136.96 million.
The extent of productivity of a business whose workforce counts for 408 workers is very important to gauge. In terms of profitability, gross margin is 86.84%, operating margin of -707.97%, and the pretax margin is -715.51%.
Vir Biotechnology Inc (VIR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vir Biotechnology Inc stocks. The insider ownership of Vir Biotechnology Inc is 36.22%, while institutional ownership is 51.30%. The most recent insider transaction that took place on Apr 03 ’25, was worth 474,239. In this transaction Chief Executive Officer of this company sold 79,712 shares at a rate of $5.95, taking the stock ownership to the 769,505 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Officer and Director proposed sale 79,712 for $5.95, making the entire transaction worth $474,239.
Vir Biotechnology Inc (VIR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 12.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.12% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
You can see what Vir Biotechnology Inc (VIR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.83, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.07 in one year’s time.
Technical Analysis of Vir Biotechnology Inc (VIR)
The latest stats from [Vir Biotechnology Inc, VIR] show that its last 5-days average volume of 1.54 million was inferior to 2.02 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 32.43%. Additionally, its Average True Range was 0.52.
During the past 100 days, Vir Biotechnology Inc’s (VIR) raw stochastic average was set at 6.11%, which indicates a significant decrease from 25.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.98% in the past 14 days, which was lower than the 101.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.87, while its 200-day Moving Average is $8.36. Now, the first resistance to watch is $5.64. This is followed by the second major resistance level at $5.76. The third major resistance level sits at $5.96. If the price goes on to break the first support level at $5.32, it is likely to go to the next support level at $5.12. Assuming the price breaks the second support level, the third support level stands at $5.00.
Vir Biotechnology Inc (NASDAQ: VIR) Key Stats
There are 137,143K outstanding shares of the company, which has a market capitalization of 758.38 million. As of now, sales total 74,210 K while income totals -521,960 K. Its latest quarter income was 12,370 K while its last quarter net income were -104,590 K.
